Understanding how specific molecules affect blood cell formation
Official title: Project 3: Role of Glycosaminoglycans in Hematopoiesis
Funded at Versiti Wisconsin, INC. · NIH-11001983 · Data updated 2026-11-12
This study is looking at how certain sugars in the body, called glycosaminoglycans, help make and support blood cells in the bone marrow, with the goal of finding new ways to treat blood disorders.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | January 1, 2021 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $530,659 |
| NIH project number | 5P01HL151333-05 |
| Project ID | NIH-11001983 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with conditions affecting blood cell production, such as anemia or leukemia.
✕Less likely to help
Patients with stable blood cell counts and no underlying hematological conditions may not benefit from this research.
What this research studies
This research investigates the role of glycosaminoglycans (GAGs) in the formation and function of blood cells, particularly in the bone marrow environment. The project aims to identify the specific sequences of GAGs that influence blood cell development and survival, as well as their potential therapeutic applications. By developing new technologies and synthetic GAG mimetics, the research seeks to clarify how these molecules can modulate hematopoietic outcomes, which could lead to improved treatments for blood disorders.
Why it matters
Potential benefit: If successful, this research could lead to new therapies for patients with blood disorders by enhancing our understanding of blood cell formation.
How similar studies have gone: Other research has shown promising results in understanding the role of similar molecules in blood cell development, indicating that this approach has potential for success.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Desai, Umesh Ramanlal — Versiti Wisconsin, INC.
- Study coordinator: Desai, Umesh Ramanlal
Related research
Other NIH-funded projects on the same topics.
-
Improving blood safety and availability for transfusions in children and adults
This study is looking to make blood transfusions safer and more accessible for both kids and adults by gathering information from blood donors and recipients across the US and Brazil, so that everyone can benefit from better transfusion practices in the future.
-
Understanding how to safely increase fetal hemoglobin for treating blood disorders
This study is looking at how to safely boost fetal hemoglobin levels in people with blood disorders like beta-thalassemia, by exploring new ways to change certain cells in the body, so that patients can have better treatment options.
-
Understanding how certain proteins regulate blood clotting and cardiovascular diseases
This study is looking at how two proteins that help with blood clotting and heart health work, which could lead to better treatments for blood clotting disorders and heart disease.
-
Targeting a specific gene to treat a type of leukemia
This study is testing a new treatment called AI-10-49 for people with acute myeloid leukemia who have a specific genetic change that makes their condition harder to treat, and it aims to help these patients live longer by killing leukemia cells and working better with other medications.
-
Understanding maternal immune responses affecting newborns with low platelet counts
This study is looking at how a mother's immune system can affect her baby's platelets, which might lead to a serious bleeding condition in newborns, and it aims to find out which pregnancies are at higher risk so that better tests and prevention methods can be developed to help keep babies safe.
-
Understanding the immune response in patients with heparin-induced thrombocytopenia
This study is looking at how the immune system responds to heparin, a blood thinner, to find out more about a serious condition called heparin-induced thrombocytopenia (HIT), and it aims to help doctors better identify harmful antibodies in patients, even if their regular tests come back normal, so they can prevent ser
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.